Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of remternetug versus placebo in early Alzheimer's disease
CTR20250052Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started May 2025; status: active.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20250052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250052.